Abstract: Inflammation is a complex pathological condition associated with exaggerated human immune system involving various activated immune cells and bio-molecules. Treatment of inflammatory diseases perticularly chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease etc. has been a big challenge for scientists as there are no safe drugs available for cure. Current therapeutic approaches to the treatment of inflammatory diseases are centered on cycloxygenase (both COX-1 and 2) proinflammatory enzymes but present available drugs of this category are associated with undesirable gastrointestinal and cardiovascular side effects. Recent scientific advents draw out the secrets of inflammation cache and understanding the involvement of several factors acting as stimulators or inhibitors thus opening new avenues for drug discoveries. Several bio-molecules such as proinflammatory cytokines, components of signal trasduction and matrix degrading enzymes resolve inflammatory responses, might be new targets for treatment of chronic inflammatory diseases. This review gathers recent advances in drug research focusing interleukin-1, TNF-α, p38 kinase, c-Jun N-terminal kinase MAP kinase, NFκB, and matrix metalloproteinases. The biological roles of these inflammatory mediators are clearly understood thus offering new targets for design of novel inhibitors for incurable inflammatory diseases. This also provides an overview of the current nonsteroidal antiinflammatory agents.
INTRODUCTION
Inflammation is normal and vital protective response to the harmful stimuli such as infectious agents, antigen-antibody reactions, thermal, chemical, physical agents, and ischemia. Inflammation is the result of activation of cellular elements and presence of various biochemical mediators have been reviewed [1] . Cyclooxygenase (COX) [2, 3] and lipoxygenases (LO) [4, 5] catalyse arachidonic acid to form prostaglandins and leukotrienes and were the attraction for developing antiinflammatory drugs [6, 7] . Nonselective COX inhibitors like aspirin were used to treat the inflammatory diseases but suffered from serious gastrointestinal (GI) side effects [8, 9] . Selective COX-2 inhibitors afforded alternative approach to arthritic treatment with little gastrointestinal side effects but on long-term usage led to serious cardiovascular and thrombotic side effects and are under the critical surveillance [10] [11] [12] [13] [14] . Many LO inhibitors were successfully employed to treat asthmatic patients but were little effective in arthritis and other chronic inflammatory diseases [15] [16] [17] [18] . Further, pathophysiological studies indicate the presence of other chemical mediators such as interleukins (IL-1, 6 and 8) [19] [20] [21] [22] [23] [24] , tumor necrotic factor-α (TNF-α) [25] [26] [27] [28] , mitogen activated protein kinases (MAP kinase) [29] [30] [31] [32] [33] , transcription factors and zinc dependent matrix metalloproteinases (MMP) etc. These bio-chemicals play a vital role in the progression of inflammation and inhibition of such inflammatory mediators can relieve the inflammatory diseases thus offering new targets for antiinflammatory drugs. Few inhibitors are currently in the market for treatment of rheuma-*Address correspondence to this author at the University College of Pharmaceutical Science, Kakatiya University, Warangal. 506 009 (A.P), India; Tel: +919440601054; Email: achaiah_g@yahoo.co.in toid arthritis (RA) and many of inhibitors are in the various phases of clinical trials. This review highlights the role played by these mediators in the pathology of inflammatory diseases and the progress in the novel inhibitors search targeting these chemical mediators. Special mention of the existing antiinflammatory agents with their activity is given in the current review.
CHEMICAL MEDIATORS INVOLVED IN INFLA-MMATION

Arachidonic acid derivatives
Derivatives of long chain unsaturated fatty acids such as arachidonic acid (unsaturated acid containing 20 carbon) play a significant role in various biological process including inflammation. Arachidonic acid under the action of various cytosolic enzymes form eicosanoids, like prostaglandins (PG), leukotrienes (LT), thromboxanes (TX) and prostacyclins [5, 34] .
COX Pathway
The essential fatty acids of diet are esterified with phosphate into phospholipids. Many stimuli (IL-1 stimulation) activate cytosolic phospholipase A 2 that cleaves membrane bound phospholipids hydrolytically to form free arachidonic acid, which is further metabolized through cellular enzymes [35] . COX a microsomal enzyme, which is also called endoperoxide synthase or prostaglandin endoperoxide H synthase forms precursor prostaglandin PGH 2 by addition of oxygen to arachidonic acid [3, [36] [37] [38] . There are two vital functions of COX namely, endoperoxide synthesis (endoperoxide synthase activity) and formation of PGH 2 (peroxidase activity). Both PGG 2 and PGH 2 decompose rapidly as they are chemically unstable. PGE 2 isomerase converts PGH 2 to PGE 2 . PGD 2 is formed by the actions of isomerase, glutathione S transferase on PGH 2 [39] [40] [41] . PGH 2 under the influence of thromboxane synthase forms thromboxane A 2 that further breaks into stable thromboxane B 2 and 11-dehydro TXB 2 . By the action of prostacyclin synthase PGH 2 is converted to PGI 2 (Fig. 1) .
Eicosanoids have diverse pharmacological actions, they contract and relax smooth muscles [42] . PGE 2 contracts uterine smooth muscle thus it is generally employed as an abortifacient and it is also potent stimulant of smooth muscle of GI. PGs are the key regulators of cellular processes like cell adhesion, proliferation and cell migration. They are also involved in pathology of cancer [43] . PGs are potent vasodilators thus systemic blood pressure falls while thromboxane A 2 is vasoconstrictor. PGs can elevate body temperature. Most potent PGs involved in inflammation are PGE 2 , PGD 2 , PGF 2α , PGI 2 and thromboxane A 2 .
Cytokine Networks (IL's/TNF, p38 and JNK MAPK, NFκB)
Proinflammatory cytokines such as IL-1 and TNF-α are produced in many inflammatory diseases [44] . Pathology of many autoimmune diseases like RA, multiple sclerosis, inflammatory bowel disease, insulin dependent diabetes mellitus, ankylosing spondylitis, Crohn's disease (CD) and Hashimoto's thyroiditis revealed the presence of proinflammatory cytokines [45] [46] [47] [48] . IL-1 along with IL-6 and TNF-α are important proinflammatory cytokines that are produced from Fig. (1) . Cyclooxygenase pathway of formation of arachidonic acid products [261] . (Fig. 2) . I kappaB protein is phosphorylated then dissociated from NF-κB with subsequent moment into nucleus and binding to regulatory DNA sequences [56, 57] . 
Complement System
Complement system is a vital part of the immunoinflammatory response in host defense that aids in the elimination of various microorganisms and antigens from host body. Apart from the important role in defense mechanism, complements have interesting role in the inflammatory responses [58] . Activation of the complement cascade results in the formation of anaphylotoxins C3a, C5a and the membrane attack complex, which lyses bacterial cells. Excessive complement activation has been associated with a diverse range of immunoinflammatory diseases such as septic shock [59] , adult respiratory distress syndrome [60] and RA [61] . Both C3 and C5 are present in inactive form and are activated in two different pathways: the classical pathway which is initiated by the antigen-antibody complex and leads to fixation of complement C1 (preferably IgG or IgM) while microbial products trigger alternative pathway. In both pathways C3 is cleaved into C3a and C3b by C3 convertase. C3b then combines with C5 convertase thus forms C5a and C5b fragments. C5a initiates the membrane attack complex that causes the lysis of the target cells. This hormone like peptide is an important part of the human inflammatory and immune system acts on blood vessels, smooth muscle, mast cells, and peripheral blood leukocytes and result in the release of secondary inflammatory mediators. C5a causes smooth muscle contraction, vasodilation/vasoconstriction and increased vascular permeability, mast cell degranulation (histamine release) increased intracellular calcium mobilization [62] [63] [64] [65] [66] [67] [68] , stimulation of the oxidative metabolism of polymorphonuclear leukocytes (PMNs) [69] , enhanced antibody production, synthesis and release of cytokines such as IL-1 IL-6, IL-8, TNF-α, PGs and LOs from inflammatory cells [70] [71] [72] 63] . C5a is also one of the most potent chemotactic agents known, inducing the migration of leukocytes in a specific direction along its concentration gradient to the site of infection or injury and stimulates release of their active components [73, 74] (Fig. 3) .
ANTIINFLAMMATORY AGENTS
Various targets of antiinflammatory agents have been shown in Fig. (4) .
Nonsteroidal Antiinflammatory Agents
NSAIDs are the most widely used drugs in the community for rheumatologic as well as nonrheumatologic conditions, which include acute and chronic pain, biliary and ureteric colic, dysmenorrhea and fever. The antiinflammatory activity of NSAIDs is due to their ability to inhibit the COX.
COX Inhibitors
COX a microsomal enzyme converts arachidonic acid to the prostaglandin precursor PGH 2. In 1971 Vane identified the enzyme COX as the common molecular target of the several antiinflammatory drugs like aspirin, indomethacin and ibuprofen and purified it in 1976 [75] . COX-1 is constitutively expressed in most of the tissues and produces prostanoids that mediate homeostatic functions especially in gastric mucosa, small and large bowel mucosa, kidney, platelets and vascular endothelium. A second isoform of cyclooxygenase COX-2 was discovered in 1991, which is induced by cytokines (IL-1β, TNF-α) and growth factors (FGF, PDGF, EGF). COX-2 was rapidly upregulated at in Fig. (3) . Complement cascade [263] . flammatory sites and appeared responsible for the formation of proinflammatory prostanoids. Recently a third variant COX-3 has been assumed in the pyresis, which is inhibited by acetaminophen [76, 77] .
Salicylates
Salicylic acid was first discovered from the glycoside salicin obtained from willow bark. More derivatives of salicylic acid were prepared and tested to relieve pain. Aspirin is the most successfully used antiinflammatory agent (1) [78] . Aspirin is nonselective COX inhibitor having more selectivity towards COX-1 and acts by acetylating ser530 of COX-1 and ser516 of COX-2 [79] . It also acts at the hypothalamus, causing an increase in peripheral blood flow, sweating, and therefore cooling. It also inhibits the synthesis of thromboxane A 2 in platelets and lesser extent PGI 2, therefore it is employed in coronary blockades. Arguably aspirin is the wonder drug for inflammation management but it is associated with gastrointestinal side effects resulting in distress, nausea and vomiting. Prolonged use results in gastric ulceration and gastric hemorrhage. Active part of salicylates is salicylate ion formation but the gastric activity is associated with carboxylate ion. Modifications of this carboxylic group either reduce the potency or increase the toxicity as with methyl salicylate, choline salicylate and salol. Alteration of the phenolic group also reduces the potency.
Aryl and Hetero Alkanoic Acids
Indomethacin (2), an indole acetic acid derivative was introduced in 1965 as antiinflammatory analgesic, used in RA, osteoarthritis and spondylitis and it is 2-3 times more potent than phenylbutazone. Indomethacin is associated with dose dependent side effects like gastric distress, peptic ulceration and headache. The antiinflammatory activity of indole acetic acid analogues increases with the increase in acidity of carboxylic acid while amide analogues are devoid of activity. The indole moiety in indomethacin was isosterically modified to indene resulted in useful NSAID sulindac sodium (3), which has plasma half-life 8 hrs. Sulindac is indicated in rheumatoid arthritis, ankylosing spondylitis and osteoarthritis. It is also associated with adverse effects including gastric bleeding, nausea and dizziness. One of the most promising aryl acetic acid derivatives was diclofenac sodium (4) that has structural features of the arylalkanoic acid and anthranilic acid classes. It is 450 times more potent than aspirin in antiinflammatory activity and six times more potent than indomethacin. An aryl propionic acid derivative ibuprofen (5) is widely used as an analgesic and its efficacy is comparable to that of aspirin with lower side effects but less potent than indomethacin in antiinflammatory assays.
N-Aryl Anthranilic Acids or Fenamates
Mefenamic acid (6) was the first compound introduced among fenamates class later flufenamic acid was introduced in to market with modest antiinflammatory activity. These fenamates block the production of PGs by inhibiting COX activity. Structure activity relationship shows that substitution on benzene ring bearing carboxylic acid group reduces the antiinflammatory activity while the substitution on Naryl ring has varying effect. Common side effects associated with fenamates are upper gastrointestinal discomforts with diarrhea, inflammation of bowel and skin rashes.
Oxicams
Oxicams (4-hydroxy-1,2-benzthiazine carboxamides), long acting NSAIDs and hence administered once in a day. Piroxicam (7) is more potent than aspirin in UV erythema assay and phenylbutazone in rat adjuant arthritis assay. They also inhibit the activation of neutrophils and collagenase that are involved in degradation of collagen in inflammation of joints. For the better activity the nitrogen in benzothiazine ring should be substituted with methyl group where as compounds with aryl or heteroaryl carboxamide at 3 rd position exhibited better activity. These are also associated with moderate gastrointestinal adverse effects.
Selective COX-2 Inhibitors
Many of the convensional NSAIDs are associated with gastrointestinal disturbances particularly peptic ulceration and gastric hemorrhages. This gastric adverse activity is due to nonselective inhibition of COX-1 because COX-1 is involved in synthesis of beneficiary PGs, which protect GI tract whereas COX-2 synthesizes PGs, which mediate inflammation. Thus COX-2 offers the ultimate target to discover new molecules that selectively inhibit COX-2 and devoid of gastric adverse effects [80] . Both COX-1 and COX-2 have 70% identical amino acid homology but they are the products of two different genes that reside on different chromosomes. The amino acid sequence at the active site is also different, in COX-2 a bigger binding site as compared to COX-1. This is due to presence of smaller amino acids in the active site of COX-2 [81] .
Many five member heterocyclic compounds have been synthesized and tested for selective COX-2 inhibition. Rofecoxib (8) is the first diaryl furanone marketed in 1999 as selective COX-2 inhibitor. Rofecoxib (Vioxx) possesses antiinflammatory, analgesic and antipyretic activity and it is indicated in the treatment of RA, acute pain and primary dysmenorrhea. Gastric injury has been reported on long-term use of rofecoxib and it should also be used very cautiously in patients with congestive cardiac failure and hypertension. In September 2004 refecoxib has been withdrawn from the market as the studies revealed that rofecoxib has been associated with cardiovascular and thrombotic adverse effects. This cardiovascular adverse activity of refocoxib has been studied extensively by VIGOR (Vioxx Gastrointestinal Outcomes Research) and the study revealed that patients treated with rofecoxib have lower incidences of GI disturbance but number of heart attacks reported was higher [83] [84] [85] when compared with naproxane. The cardiovascular and thrombotic activities of rofecoxib have been attributed to the imbalance between prostacyclin and thromboxaneA2 that may lead to ischemic effects [86, 87] . Celecoxib (9) is another selective COX-2 inhibitor having diaryl pyrazole ring approved in 1999. It is indicated in osteoarthritis and RA with less gastric adverse action [82] . Other second generation aryl substituted heterocyclic compounds have been synthesized and tested for selective COX-2 activity valdecoxib approved in 2001 while several other molecules are under the clinical trials such as etirocoxib and parecoxib. Meloxicam now is an off patent demonstrated selective COX-2 inhibition. However patients treated with selective COX-2 inhibitors and their cardiovascular adverse effects are not still clear [88, 89] and detailed investigations are needed.
C5a Complement and C5a Receptor Antagonists
C5a, an anaphylotoxin is a 74 amino acid protein activated excessively during inflammation by the complement cascade. Both C3a and C5a exert their actions by binding with receptors located on cell surface of myeloid that belong to the G protein coupled super family of rhodopsin like receptors (e.g., neutrophils, eosinophils, monocytes, T lymphocytes, and macrophages), and nonmyeloid cells [90] [91] [92] [93] [94] . C5/C5a play central role in the progress of inflammation in various diseases, thus inhibition of C5a can control the inflammation. C5a receptor antagonists attract the attention as a new target to design antiinflammatory agents. The interaction pattern of C5a with its receptor is well understood, a "two-site binding" model has been proposed and C-terminal region of C5a may fit into a binding pocket formed around the fifth transmembrane domain "effector site" [95] . C5a receptor antagonists are of two types such small peptides and nonpeptides.
Few reports indicate that C5a actions can be blocked by anti-C5a antibodies, which inhibited the complement induced inflammation in rats and primates [96] and also resulted in decreased polymorphonuclear cells activity in vitro including chemotaxis, chemiluminescence and lysosomal enzyme release [97] . Based on the C5a and C5a receptor interactions, Pellas et al. designed peptide entagonists consisting of 64-75 aminoacids of carboxy terminal of C5a [98] . Modification at this tail would make antagonistic property retaining other peptide portion intact. Two new C-terminal tail truncated cysteine containing antagonists have been reported namely C5aRAM a monomer and C5a RAD a dimmer have antagonistic activity on neutrophils in vivo without agonistic activity with Ki 79 and 2 pM [99] . Angela et al. synthesized cyclic, noncyclic peptides and studied the structure activity relationships of derivatives of MeFKPdChaWr. This study attempted to stabilize the bioactive conformation of MeFKPdChaWr side chain to backbone cyclizations of the peptide assuming that cyclization would increase the receptor binding affinity and antagonistic potency while reducing the peptide character. This SAR also indicated that C-terminal L-arg has more potency than D-arg. Replacing N-terminal phenylalanine with other aminoacids resulted in decreased affinity for the receptor. Replacement of ornithine by lysine, tryptophan and others did not affect much on receptor binding [101] .
Many nonpeptide small molecules have been synthesized and screened for C5a receptor antagonistic activity. Hiroshi Sumichika et al. have synthesized N-(4-dimethyl amino) phenyl methyl N-(4'-isopropyl)-phenyl-7-methoxy-1,2,3,4-tetrahydronaphthalen-1-carboxamide (10) that inhibited binding of 125 I-labeled C5a to human neutrohils with Ki 2.2 nM. This also inhibited C5a induced Ca +2 mobilization, chemotaxis, and super oxide species generation in human neutrophils [102] . Substituted 4,6-diaminoquinolines were reported to possess weak C5a antagonistic property targetting the Site 1 binding region of the C5a receptor [103] .
IL-1 and ICE Inhibitors
Interleukin-1, a 15-17kDa molecular weight peptide, exists in two isoforms IL-1α and β produced mainly by activated macrophages and monocytes. It is associated with wide range of biological activities acting on many cells and plays and important roles in inflammation [104, 105] . IL-1β is expressed in its inactive form as IL-1β precursor (pro-IL-1β) having 31kDa molecular weight. This pro-IL-1β is endoproteolytically cleaved by a cysteinyl protease called interleukin-1β converting enzyme (ICE, also called Capsase-1) at Asp116-Ala117 to generate active IL-1β [106] [107] [108] . The mature ICE made up of 404 amino acids is heterotetramer consisting two subunits p20 and p10 which are bound noncovalently. Cys285 of p20 subunit is the catalytic center [109] . Both the IL-1α and β elicit their biochemical activities by interacting with two surface receptors IL-1RI and IL-1RII. Therapeutic agents that block the activities of IL-1 may present alternate approach to treat the patients suffering from inflammatory diseases [110] .
A small peptide found in many cells that have antiinterleukin-1 activity are known as IL-1 receptor antagonist (sIL-1Ra) which is also called Anakinra that bind to both IL-1RI and IL-1RII with high affinity competitively thus preventing the IL-1 binding with the receptors [111] . At least three isoforms of this IL-1Ra have been identified. An 18kDa IL-1Ra found in keratinocytes and epithelial cells is called icIL-1Ra1, another 21kDa IL-1Ra cloned from human leukocytes called icIL-1Ra2 while 15kDa IL-1Ra known as icIL-1Ra3 is found in monocytes, macrophages and neutrophils [112] . Arend reported that administration of IL-1Ra daily by subcutaneous injection is efficacious in the treatment of RA [113] .
ICE Inhibitors
The important activity of ICE is to form mature IL-1β. Inhibition of ICE is thus regarded as a potential approach for the treatment of inflammation and arthritis. Several peptides and nonpeptides have been designed, synthesized and tested for ICE inhibition. The peptide inhibitors are designed based on the unique specificity of the enzyme at P1 for aspartic acid, thus aspartic aldehydes and alfa substituted aspartic acid methyl ketones (11) have exhibited reversible and irreversible ICE inhibition respectively [114] . Some of methylene ketones are modified for improved P1 binding with enzyme [115] [116] [117] . Some of peptides were designed as constrained dipeptides [118] . Many reports have been published on nonpeptidomemetic ICE inhibitors containing pyridinone or pyrimidone scaffolds [119, 120] . Laufersweiler et al. reported tricyclic pyrrolopyrimidinone dipeptides as ICE inhibitors, many of the analogues exhibited potent ICE inhibition activity with selectivity over Capsase-3 [121] .
A series of pyridazine (12) derivatives have been reported to exhibit ICE inhibition. The structure activity relationship of them indicates that pyridazine nucleus is essential for activity. Replacing pyridazine with pyridine nucleus resulted in loss of enzyme inhibitory activity [122] [123] [124] . Recently aryl and hetero aryl substituted imidazoles have been identified as potential inhibitors of IL-1β and other proinflammatory cytokines like TNF-α [125] [126] [127] . The pyrimidinylimidazole derivatives have been reported as potential IL-1 production inhibitors [128] .
TNF-α and TNF-α Converting Enzyme Inhibitors
TNF-α, a proinflammatory cytokine is synthesized by activated macrophages and T cells in human body [129, 130] . It is formed by the action of an enzyme called TNF-α converting enzyme (TACE) on proTNF-α by cleaving AlaVal bond [131] . TNF-α activates various cells by binding to its receptors (TNFR) that trigger signaling pathways leading to various inflammatory diseases [132] . The vital inflammatory activities of TNF-α offer a novel target for the development of agents to treat inflammatory diseases. The inhibition of TNF-α activities can be achieved by suppressing its production and release from activated inflammatory cells or inhibiting the TNF-α from its binding to its receptors TNFR.
TACE Inhibitors
Several TNFα inhibitors like TNF neutralizing antibodies (anti-TNFα antibodies Ramicade R ) and soluble protein receptors (Enbrel R ) have been used in RA and CD but these agents have to be administered only parenterally. Therefore development of small nonpeptide molecules with TNF-α inhibitory activity could be a suitable therapeutic approach for treatment of RA. Thus TACE can be targeted with new small molecules for the chronic inflammatory diseases. TACE is a member of the ADAM (a disintegrin and a metalloprotease domain) subfamily of the metzincin super family, which also includes astacins, serralysins and MMPs [133, 134] . X-ray crystal structure of TACE indicates low homology with MMPs, but significant similarity at the active sites. Because of this similarity, several broad-spectrum MMP inhibitors have also the ability to inhibit TACE, thus inhibiting the production of TNF-α [135] .
Michael et al. have reported novel TACE and MMP-13 inhibitors based on piperazine-2-hydroxamic acid (13) scaffold that were devoid of MMP-1 activity. All the compounds in this series have exhibited potent TACE inhibitory activity (<50nM) and with few exceptions also MMP-13 inhibitory activity. The effect of substitution on the piperazine nitrogen and the benzyloxy tailpiece has been studied. The benzyl tailpiece on these analogues is too large to fit in the smaller P-1 / pocket of MMP-1 thus did not show any MMP-1 inhibition activity [136] . Chen et al. studied the SAR of novel piperazine series and optimized the lead compound. They also discussed the effect of substituent on piperazine ring [137] . These broad-spectrum TACE inhibitors have exhibited side effects in clinical trials [138] , thus it is required to search for new selective TACE inhibitors. James et al. discovered new N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamide scaffold as selective TACE inhibitors. Many of the compounds in this series inhibited TACE at concentration lesser than 5 nMs having many folds selectiv-ity with respect to MMP-1 and MMP-2 [140] . Phosphonamide (15) based derivatives have been tested for selective TACE inhibition [141] . Some new phosphonamides were designed based on isoquinoline phosphonamide lead and Sisomers at phosphorous exhibited potent selective TACE inhibition [142] .
TNF-α Production Inhibitors
Several small molecules are synthesized and tested for TNF-α production inhibitory activity in LPS induced TNF-α model. Many thiophenes and bicyclic thiophenes have been synthesized and evaluated for inhibition of TNF-α production, some compounds exhibited significant inhibitory activity [143, 144] (16). Thalidomide a sedative without the side effects of barbiturates [145, 146] is reported possess antiinflammatory activity, which is found to be due to inhibition of TNF-α production from monocytes [147, 148] . New series of aminosubstituted thalidomides [149] , aza analogues [150] (17) and perfluorinated thalidomides [151] are synthesized and evaluated for TNF-α production from various activated cells in vitro. 
p38 Kinase Inhibitors
p38 kinase is a member of MAP kinase involved in multiple signaling processes, which is activated in inflammation by LPS, stress or cytokines [152] . Activation of p38 MAP kinase along with capsase-1 is involved in apoptosis of cells and activation of transcription factors that are responsible for production of proinflammatory cytokines [153, 154] . It has been found that p38 MAP kinases are involved in LPSinduced mesencephalic neurons death in rats [155] and phosporylation of transcription factors responsible for 5-LO synthesis [156] . Increase expression of COX-2 has been reported due to oxidative stress in antigen stimulated mast cells is mediated by p38 MAP kinases resulting in increased levels of eicosanoids [157] . Hence inhibition of p38 MAP kinase forms a new strategy for treatment of inflammatory disease [158] [159] [160] [161] .
Aryl or hetero aryl substituted imidazoles like pyridinyl imidazoles (18) have been identified as potential leads for p38 MAP kinase inhibition. Previously triaryl imidazoles were known as cytokine production inhibitors, but isotopically labelled studies revealed that imidazoles bind p38 is molecular target. Generally pyridine at the Ar 1 or Ar 2 demonstrated better p38 MAP kinase inhibition activity which is attributed to strong hydrogen bond formation between the nitrogen of pyridyl with NH of Met109 and penetration of aryl group into hydrophobic area of the enzyme that is not accessed by ATP's [162, 163] . The crystallographic studies and biochemical informations reveal that pyridinyl imidazole compete at the ATP binding site of the enzyme [164, 165] . Though pyridinyl imidozoles are potent p38 kinase inhibitors but they are also found to be hepatotoxic due to interference with hepatic cytochrome P450. Thus extensive research has been done to separate the p38 inhibition and hepatotoxicity of pyridinyl imidazoles as both imidazole and pyridine are known ligands for hepatic cytochrmome P450 [166] . Pyridine in the imidazoles has been replaced by substituted pyrimidine that afforded compounds with excellent in vitro and in vivo p38 inhibtion with reduced P450 interference [167] [168] [169] [170] [171] . The imidazole ring has been fused to form imidazopyridine [172] and benzimidazolones, modified to saturated or unsaturated pyridopyrimidines [173] [174] [175] , and pyridazines [176] [177] [178] for evaluation as p38 kinase inhibitors.
Dihydroquinazolinones (19) have been synthesized and tested for p38 MAP kinase inhibitory activity [179] [180] . Binding interactions infer that dihydroquinazolinones have similar binding interactions with enzyme as those of pyrimidynyl/ pyridinylimidazoles. The carbonyl group at the 2 nd position is involved in hydrogen bond formation with the enzyme backbone, which is similar to the hydrogen bond formed by the nitrogen of pyridine or pyrimidine ring in imidazoles. The dihydroquinazolinones make three hydrogen bonds with the enzyme backbone Leu107, Met109 and Gly110 and 2, 6-dichloro phenyl moiety occupies the same position as of the aromatic group of pyridinyl aryl imidazoles [181] .
Ureas substituted with pyrazoles (20) [182] [183] , theophines [184] , alkyl substituted isoxazoles [185] and purines [186] were discovered as novel p38 kinase inhibitors. The molecular modeling and crystallography information reveal that urea group acts as hydrogen bond donor and acceptor site. Disubstituted ureas containing t-butylpyrazoles bind with the allosteric domain of p38α other than ATP binding site. BIRB 796 a pyrazole urea derivative is in the clinical phase II trials, exhibited inhibition potency in picomolar concentration. The crystallographic examinations reveal that large conformational changes occur when the urea inhibitor binds with the kinase. The side chain of Phe169 moves away by ~10Å such that one phase of side chain shields inhibitor while other phase of the side chain interacts with the solvent molecule, thus creating a large space where t-butyl group of the pyrazole in the inhibitor penetrates deep inside. Aromatic substitution has also been studied, the pendant aromatic groups preferably meta or para substituted phenyl rings have demonstrated strong p38 kinase inhibition [187, 188] . A novel series of nonheterocyclic bisamides have been discovered through selective screening and exhibited selectivity towards other protein kinases [189] .
Leftheris et al. have identified a new lead containing triazine scaffold as p38 kinase inhibitor. Various triaminotriazine aniline derivatives have been screened for p38 kinase inhibition and the lead was modified for further improvement in the potency. An analogue with amide substituted anilino and diazapinotriazine compound has been subjected for its binding interaction with the kinase. The crystallographic study exposes that triazine analogues compete ATP at ATP binding site. Unlike pyridinylimidazoles, triazine aniline analogues make indirect H-bond with Met109 through water molecule while methoxy amide forms hydrogen bond with Glu71 and Asp168 [190] .
Vertex (Vertex Pharmaceuticals Cambridge USA) in their annual report indicated that the molecule VX-745 had to be discontinued after clinical trials phase II due to adverse effects on CNS, while few p38 inhibitors VX-702 and VX-850 (structures not disclosed) have shown encouraging results in phase II clinical trials to study the safety, tolerability and clinical activity. Scios (Scios Inc.) in their annual report informed that SCIO-469 (Structure not disclosed) completed phase II trials while second generation SCIO-323 entered in phase I clinical trials.
c-Jun N-Terminal Kinase Inhibitors
The c-Jun N-terminal kinases (JNK) are evolutionarily conserved family of serine/threonine MAP kinases. JNK was identified in 1990 as 54 kDa stress activated protein kinase [191] . Like p38 MAP kinases, JNKs are activated by proinflammatory cytokines such as TNF-α and IL-1β as well as environmental stress, such as anisomycin, UV irradiation, hypoxia, and osmotic shock [192] . Members of the JNK family (JNK-1, 2 and 3) act as an integrated unit for multiple intracellular biochemical signals governing a wide variety of cellular processes such as proliferation, apoptosis, migration and transcriptional regulation [193] [194] [195] [196] [197] . JNKs are activated by their serine/threonine upstream kinases, mitogen activated protein kinase kinase (MKK) namely MKK4 and MKK7 [198] . MKK4/7 are activated by the upstream kinases called mitogen activated protein kinase kinase kinase MEKK, mixed lineage kinases (MLK1-3) [199] , Tpl12, ASK and TAK [200] [201] (Fig. 2) . JNKs are known to activate further downstream substrates, which include several transcription factors. c-Jun, acting within the activator-protein-1 (AP-1) complex, is an important transcription factor that is activated by phoshphorylation mediated by JNK [202] . The other transcription factors that are activated by JNK are AFT2 and Elk-1 [203] . Activated AFT2 heterodimerizes with c-JUN and stimulates the expression of c-jun gene whereas activated Elk-1 is involved in induction of the c-fos gene that induces heterodimer formation of AP-1 with c-Jun [204] . Activation of AFT2 and c-Jun transcription factors activate the promoters of MMP genes and c-Jun itself, that lead to expression of matrix metallo proteinases that degrade type II collagen in rheumatoid arthritis.
JNK Inhibitors
In the view of important role played by JNK, its inhibition has been reported to be a valuable approach in development of agents for the treatment of oncological, apoptosis related and inflammatory diseases (neurodegenerative diseases, ischemia reperfusion injuries, multiple sclerosis, rheumatoid arthritis) [206] . A specific JNK inhibitor, SP 600125 an anthrapyrazole derivative (anthrax-[1,9-c,d]pyrazol-6-(2H)-one), was identified during high through put screening. SP 600125 is competitive inhibitor of JNK binding at the ATP binding site. It has shown to be active against all isoforms of JNK having 300 folds selectivity over other MAP kinases. These anthrapyrazole derivatives are associated with disadvantage of having low water solubility hence several modifications have been tried to improve the potency. The SAR infers that N-alkyl substitution decreased the activity whereas introduction of chlorine at 8 th position augmented the activity with increased water solubility [208] .
Gaillard et al. reported benzothiazolyl pyridine (3H-benzothiazol-2-ylidene-6-bromo-2-chloropyrimidin-4-yl) acetonitrile benzothiazole (AS-007149) as a prospective JNK inhibitor by library search and the effect of structural modifications on JNK inhibition. The SAR revealed that the benzothiazol-2-yl acetonitrile pyridine core plays a role in retaining a good level of JNK inhibition. Alterations in core scaffold such as conversion of benzothiazole to benzimidazole decreased the activity. The decreased activity has also been noticed when cyano group was substituted by carboxy ethyl and a methyl substitution on nitrogen. Substitution of 2-chloro group of pyrimidine ring with secondary amines resulted in increased activity [209] .
Another high through put screening identified 3-(4-pyridyl)-indazole as novel scaffold for JNK inhibition with pIC 50 
NFκB and IKKβ Inhibitors
NF-κB is a redox sensitive transcription factor, heterodimeric protein composed of different transcription factors of the Rel family of [212] . NF-κB is composed of homo and heterodimers of five members of the Rel family including NF-κB1 (p50), NF-κB2 (p52), RelA (p65), RelB and c-Rel (Rel) [213] . NF-κB resides in the cytoplasm of the cell in inactive form and is bound to its inhibitor protein called IKappaB (IκB) noncovalently. Seven isoforms of IκBs have been identified namely IκBα, IκBβ, I-κBγ, IκBε, BCL3, p100 and p105 containing 30-35 aminoacids [214] . NF-κB can be activated by LPS or inflammatory cytokines and free radicals which results in phoshphorylation of IκBs by IKappaB Kinase Complex (IKK) on the conserved serine residue at N-terminal portion of IκB [215] [216] [217] . Activated NF-κB complex translocates into the nucleus and binds DNA at Kappa-B binding motifs such as 5-prime GGGRNNYYCC 3-prime or 5-prime HGGARNYYCC 3-prime and induces gene expression and further expression of cytokines, chemokines, growth factors, cellular ligands, and adhesion molecules [218, 219] . NF-κB plays a role in several diseases, such as asthma [220] , neurodegeneration, ischemia/reperfusion injury, hepatitis, glomerulonephritis and inflammatory bowel disease [221] [222] [223] . RA is characterized by the production of inflammatory mediators, many of which are regulated by the Rel/NF-κB transcription factors including [224, 225] .
The potential role played by NF-κB in inflammation opened another feasible approach to control these inflammatory diseases. Alexi et al. concluded that inflammatory cytokines, including IL-1β, IL-6, and TNF-α are induced by the activation of NF-κB in synoviocytes [226] .
Two catalytic subunits, IKKα (IKK-1), IKKβ (IKK-2) and regulatory subunit IKKγ (IKKAP1) are identified in IKK. IKKα is an 85 kDa, a serine threonine kinase whereas IKKβ is 87kDa protein with 50% structural similarity with IKKα. IKKγ (NEMO) is a 50 kDa containing several Nterminal helical regions. TNF-α interaction with the cell surface receptors activates adaptor protein called TRAF2 which intern activates NIK, NIK further activates IKK by phoshporylation.
Jue et al. reviewed the drugs that suppress the NF-κB and their usefulness in controlling RA [227] . Many of the NSAIDs such as aspirin and sodium salicylate have demonstrated to result in NF-κB inhibitory activity followed by inhibition of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) [228, 229] , which are encoded by NF-κB target genes. Aspirin and sodium salicylate are found to be competitive inhibitors of ATP at ATP binding pocket of IKK-β there by hindering the degradation of IκBβ. Synthetic glucocorticoids inhibit the NF-κB gene expression and transcription of many proinflammatory cytokines and cell surface molecules that are involved in inflammation responses. Glucocorticoids also increase the transcription of IKB proteins that bind to NF-κB in the cytoplasma [230, 231] . Thalidomide (which is called immunomodulatory drugs IMiD) once known as teratogenic sedative, anti-angiogenic, immunosuppressive and antiemetic agent is reported to have antiinflammatory activity. Its anti-inflammatory activity is due to suppression of proinflammatory cytokine expression and modulating the levels of vascular endothelial growth factor (VEGF). This cytokine expression is related to inhibition of NF-κB activation [232, 233] through suppression of IKK activity [234] . Some of the analogues CC-4047 and 5013 are in various stages of clinical trials and have shown promising results for the treatment of cancers.
Some metabolites of prostaglandins namely cyclopentanone prostaglandins (CyPGs) possess anti-inflammatory activity, which is attributed to the inhibition of NF-κB. This anti-inflammatory activity is probably due to activation of peroxisome proliferation activated receptor-γ that is known to inhibit NF-κB transcriptional activity [234, 235] .
The mutational studies infer that IKKβ has vital role in activation of NF-κB in inflammatory diseases, thus specific inhibitors of IKK may be suitable for inflammatory diseases, but the disadvantage associated with inhibition of IKK is the increased susceptibility to induction of programmed cell death. Much progress has been taken place in finding selective IKKβ inhibitors and some of the newer molecules are in preclinical studies, which could be useful for treating the diseases like cancer and inflammation.
Several heterocyclic compounds have been identified as lead molecules to inhibit IKKβ with increased selectivity. Quinazoline analogues have been extensively studied for selective IKKβ inhibition, one of most potent compounds in this series SPC-839 with IC 50 60 nM having more than 200 times selectivity for IKKβ [236] .
BMS-345541 an imidazoquinaxaline derivative exhibited ten-folds selectivity for IKKβ (IC 50 0.3 µM) and reported to bind the allosteric center of the kinase instead of regular ATP binding site. This molecule has also inhibited LPSstimulated synthesis of proinflammatory cytokines including TNF-α, IL-1β, IL-6 and IL-8 [237] . Diaryl pyridines have been reported to possess more selectivity for IKKβ inhibition, a most potent molecule in this series exhibited in vitro inhibition of LPS induced TNF-α formation with IC 50 value 0.6 µM and in vivo inhibition with ED 50 2mg/kg body weight [238, 239] . Several new leads have been reported in literature containing heterocyclic ring systems with more selectivity towards IKKβ viz thiophenes, benzimidazoles, indoles, indazoles etc.
Matrix Metalloproteinase Inhibitors
MMPs are subfamily of metzincins functionally related to zinc dependent endopeptidases, which hydrolyze extracellular matrix in human body [240] . At least more than 24 MMPs have been identified and are divided into five subgroups based on the substrate specificity as collagenase (MMP-1, -8, -13 and -18), gelatenase (MMP-2 and -9), stromelysins (MMP-3, -7, 10 and -11), membrane type MMPs (MT-MMPs) (MMP-14, -15, -16, -17, -24 and -25 ) and nonclassified other MMPs (MMP-19, -20, -23, -26, -27 and -28) [241, 242] . Activated MMPs play a vital role in degradation of extracellular matrix during tissue repair and angiogenesis. MMP-2, -14 along with collagenases have been reported in the degradation of collagen type I, II and III [243, 244] . MMPs play critical a role in several pathological conditions like metastatic tumors and several inflammatory diseases such as inflammatory bowel disease, RA and osteoarthritis [245] [246] [247] . Activities of MMPs can be controlled in vivo at several stages such as regulation of gene expression, inhibition of active MMPs by tissue inhibitors of matrix metalloproteinsase (TIMP) and activation of zymogens [248] . Many research strategies have been evolved to decrease the biochemical actions of MMPs like obstructing one or more MMP activations. Design of synthetic molecule that inhibit MMPs aimed to mimic the natural inhibition by TIMP, but more success is associated with synthetic small molecules that bind the active site of MMPs. Zinc is the core center for MMPs activity and thus synthetic molecules are searched that bind the zinc moiety of MMPs. Several zincbinding groups have demonstrated wide range MMP inhibition. The zinc binding groups are hydroxymate, carboxylate [249] , phosphoric acid, sulfonamide, sulfyhydril, and phosphonamide and among them hydroxymates have shown encouraging activity. Previously small molecular weight peptides were the target of MMP inhibitor design, peptides were designed in such away that they mimic the nature of active site of MMPs containing zinc-chelating groups in place of scissile bond [250] . Several nonselective MMP inhibitors suffered set back during the clinical trial studies due to the unexpected adverse effects. These adverse effects of inhibitors were found to be due to inhibition of other MMPs that are involved in normal physiological functions, and inhibition of these MMPs cause excessive deposition of matrix leading to fibrosis [251, 252] . Thus selective MMP inhibitors have the advantage over the classical broad range MMP inhibitors. As the protein crystal structures of several MMPs have revealed the binding interactions between the inhibitors and MMPs thus the process of new lead identification for selective MMP inhibitors has been expedited.
Several broad spectrum and selective MMP inhibitors have been tested in animal models and human clinical trials and hydroximate MMP inhibitors like CGS-270230, RO-323555 and BAY-129566 have been well studied. BAY-129566 has selective collagenase inhibitory activity and was effective in animal, small and short level clinical trials but failed in large and long-term clinical trials [253] . Hydroxymates containing Succinyl scaffold (succinyl hydroxamates) are the first generation broad-spectrum MMP inhibitors. Batimastat (BB-94 21) and marimastat (BB-2516) are the two succinyl hydroximates developed at British Biotech [254] . The inhibitory activity of hydroxymates is due to formation of strong hydrogen bond with carbonyl group of enzyme backbone. New ilomastat analogues containing an isobutylidene group targeted to fit in S1 packet of enzyme and a 2-substituted indole analogue nucleus exhibited selective MMP-2 activity [255] .
Some new hydroxymates were designed that also contain phosphinamide zinc binding group, synthesized and tested for MMP inhibitory activity, Compounds with an R configuration at phosphorus were found to be potent inhibitors [256] . Novel cyclic MMP inhibitors are derived from piperazine carboxylic acid and the piperazine make central backbone and provide conformational stability [257] . Venkatesam et al. have synthesized and explained the structure activity relationship of a series of α-sulfonylhydroxamic acid derivatives as potent MMP inhibitors. A dialkyl substituted derivatives exhibited potent activity against MMP-9 and -13 while decreased activity against MMP-1. These derivatives have also shown to have lesser activity against TACE. [258] .
Blagg et al. reported the synthesis and MMP-13 inhibitory activity of pyrimidinetrione [259] derivatives that spare MMP-14, and thus were useful in the treatment of osteoarthritis. The deep S prime pocket of MMP-13 was used to design the molecules with increased the activity against the MMP-13. From the SAR of mono aryloxy pyrimidinetrione derivatives and crystallographic investigation shows that an aryloxy group of the most potent molecule in this series penetrates deep in the S prime pocket. Certain modifications were required in this series as there was decrease in selectivity over MMP-14. Insertion of a second aryloxy group further increased the selectivity towards MMP-13 [260] .
CONCLUSIONS
In treating the inflammatory diseases, NSAIDs and selective COX-2 inhibitors have been conventionally the most extensively used drugs till date. However, their long-term treatment has been demonstrated to have highly adverse side effects and it has been observed that the use of rofecoxib, selective COX-2 inhibitor might even lead to fatalities due to cardiovascular and thrombotic events. Proinflammatory cytokines and components of signal transduction play a central role in the pathology of inflammation, some proteinaceous cytokine inhibitors viz. infliximab were effective either as a monotherapy or in combination with other drugs effective in treating RA. Prolonged use of these cytokine inhibitors may lead to post-treatment infections and therefore there is a quest to obtain small molecules that may inhibit these proinflammatory or intracellular signals. Further, the cost effectiveness and mode of administation of the cytokine inhibitors are not at desirable levels. Apart from these proinflammatory cytokines as a target for new antiinflammatory drug discovery, the components of signal transduction like p38 kinase, JNK and NF-kappaB can be targeted. Some of small molecules that inhibit p38 kinase are in the final stages of clinical trials. The success of these inhibitors depends on how best they pass through the clinical trials for safe use in human beings. Therefore, the present review proposes that there is a paradigm shift in the drug design and discovery attempts towards anti-inflammatory diseases. Slowly the attention is drifting towards the design, synthesis and lead optimization of inhibitors for signal transduction and anti-cytokine drugs rather than NSAIDS and COX proteins. 
